20 5 2008 10 Chinese Bulletin of Life Sciences Vol. 20, No. 5 Oct., 2008 1004-0374(2008)05-0800-07 201203 (glucocorticoids, GCs) (glucocorticoid receptor, GR) GR GR GR Q571; R979 1 A Research progresses in glucocorticoid receptor and selective glucocorticoid receptor modulators LI Qun-yi, YAN Jian-hua, WANG Ming-wei* (The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) Abstract: Glucocorticoids (GCs) are widely used as anti-inflammatory therapeutics. Their physiological and pharmacological actions are mainly mediated by glucocorticoid receptor (GR). As a member of the nuclear receptor superfamily, GR is a ligand-activated transcriptional factor and plays important roles in many physiological and pathological processes. With in-depth knowledge on the molecular mechanisms involved in GRrelated signal transduction pathways, discovery of novel GR modulators has become one of the focal points in drug development, aiming at increasing efficacies and reducing side effects. In this review, we briefly describe the current understanding of molecular structure, biological functions and selective modulators of GR. Key words: glucocorticoids; receptor; modulators 1 (glucocorticoids, GCs) 20 50, 2008-05-15 2008-08-08 973 (2004CB518902) * E-mail: wangmw@mail.shcnc.ac.cn
801 Altana (Ciclesonide) (<1%) [1] () Metselaar [2] (PEG) PEG (NO) NCX-1015( ) NCX-1022( ) [3,4] (selective glucocorticoid receptor modulators, SGRMs) (glucocorticoid receptor, GR) (heat shock protein, HSP) - GR - -κb (NF-κB) -1(AP-1) GR / (glucocorticoid response elements GREs) Reichardt [5] GR (GR dim/dim ) GR GRE AP-1 GR dim/dim [6] (SGRMs) SGRMs GR NF-κB AP-1 SGRMs 2 GR GR(hGR) 5 (5q31-32) 9 [7] 2 8 hgr mrna 9 hgr mrna (hgrα hgrβ) hgrα 777 hgr hgrβ 742 hgrα [8] (hgrγ) hgrα hgrγ DNA [9] hgrα 3 ( 1) N -1 (AF-1) DNA (DNA binding domain, DBD) (zinc fingers) C (1igand binding domain, LBD) -2(AF-2) AP-1 NF-κB [10]
802 1 α (hgrα) DBD DNA Hinge LBD Zinc fingers Dimerization GRα HSP90 HSP70 HSP40 P23 (immunophilin) GRα GRα HSP hgrα GRα GRE - [11] 3 GRα GRα / GRE GRE 15 AGAACAnnnTGTTCT(n ) [12] GRα / GRE GRα-DNA [13] GRα GRα DNA GRα GRα [14] Cre/ loxp GRα 458 (GR dim/dim ) (TAT) (PEPCK) [5] (PEPCK) (TAT) (serine dehydrogenase) [15] (GS) [16] -1(lipocortin- 1) (secretory leukocyte protease inhibitor SLPI) IL-10 [17] 4 GRα GRα GRE(negative GRE ngre) (pro-opiomelanocortin POMC) (osteocalcin) / 4(withno-lysine (K) kinase-4, WNK4) GRE GRα [18-20] GRα - ( NF-κB AP-1) 2 4.1 GRα NF-κB NF-κB Rel p65/p50 NF-κB NF-κB IκB IL-1 TNF-α LPS IκB IκB 26S NF-κB NF-κB IL-1β TNF-α (GM-CSF) COX-2 inos [21] GRα NF-κB p65 NF-κB NF-κB GRα GRα NF-κB McKay Cidlowski [22] GRα p65 - NF-κB
803 NF-κB hgrα NF-κB CBP SRC-1 [23] CBP GRα NF-κB NF-κB GRα SRC-1 NF-κB GRα [24] GRα 2(histone deacytelase 2, HDAC2) p65 DNA [25] HDAC2 GRα GRα IκB IκB IκB NF-κB NF-κB [26] 1(mitogen- and stress-activated protein kinase 1, MSK1) NF-κB p65 S276 H3 S10 IL-6 Beck [27] GR MSK1 CRM1 MSK1 MSK1 p65 H3 NF-κB Lu [28] GR RhoB HO-8910 RhoB GR NF-κB 4.2 GRα AP-1 AP-1 AP-1 Jun (c-jun v-jun Jun-B Jun-D) Fos (c- Fos Fos-B Fra-l Fra-2) c-fos-c-jun AP-1 Jun N- (JNK) c-jun Jun Fos AP-1 [29] NF-κB GRα c-jun - GRα GRα (LBD) JNK MKK7-JNK MKK7 JNK c-jun JNK AP-1 [30] Olivier [31] GR 6 (TRIP6) GRα TRIP6 (nuclear TRIP6, ntrip6) AP-1 NF-κB GRα ntrip6 ntrip6 AP-1 NF-κB 4.3 GRα p38 MAPK COX-2 TNF-α IL-6 IL-8 mrna Toll 2 (TLR2) MAPK 1(MAPK phosphatase 1, MKP-1) JNK ERK p38 ( ) COX-2 mrna TLR2 [32-34] NF-κB AP-1 GRα GRα T (nuclear factor of activated T cells NF-AT) NF-AT DNA IL-4 [35] 3(interferon regulatory factor 3, IRF3) Toll 4(TLR 4) ATF p300/cbp IFN-α/β (interferon stimulated genes, ISGs) Reily [36] 1(glucocorticoid receptor-interacting protein 1, GRIP1) IRF3 IRF3 GRα IRF3 GRIP1 IRF3 5 GR GR GR / ( 2) RU24858
804 RU24858 GR AP-1 THP-1 RU24858 LPS IL-1β RU24858 [37] RU24858 [38] RU24858 RU24858 ZK216348 AL-438 AL-438 GR E-selectin IL-6 TAT AL-438 AL-438 [39] ZK216348 THP-1 (peripheral blood mononuclear cell PBMC) IL-8 IL-12 p70 TNF-α H4-II-E-C3 (TAT) ZK216348 ZK216348 / [40] Compound 25 GR (IC 50 0.8 nmol/l) IL-6 (TAT) (GS) LPS TNF-α Compound 25 TNF-α (ED 50 4 mg/kg) [41] Compound A GR GR GRE (ChIP) Compound A GR GRE Compound A TNF-α IL-6 Compound A NF-κB 2
805 p65 Compound A Compound A [42,43] Compound 60 GR GRE NF-κB (IC 50 8.69 nmol/l) Compound 60 ED 50 0.05 0.25 µg/kg [44] Compond 36(BI) (aromatase) 20% GR IL-6 [45] LGD5552 AL-438 GR GRE LGD5552 GR LGD5552 LGD5552 [46] 6 GR GR GR ZK216348 AL-438 LGD5552 [1] Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol, 2005, 116(6): 1206-12 [2] Metselaar JM, van den Berg WB, Holthuysen AE, et al. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis, 2004, 63(4): 348-53 [3] Teshima M, Kawakami S, Fumoto S, et al. PEGylated liposomes loading palmitoyl prednisolone for prolonged blood concentration of prednisolone. Biol Pharm Bull, 2006, 29 (7): 1436-40 [4] Hyun E, Bolla M, Steinhoff M, et al. Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol, 2004, 143(5): 618-25 [5] Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell, 1998, 93(4): 531-41 [6] Reichardt HM, Tuckermann JP,Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J, 2001, 20(24): 7168-73 [7] Stolte EH, van Kemenade BM, Savelkoul HF, et al. Evolution of glucocorticoid receptors with different glucocorticoid sensitivity. J Endocrinol, 2006, 190(1): 17-28 [8] Yudt MR, Jewell CM, Bienstock RJ, et al. Molecular origins for the dominant negative function of human glucocorticoid receptor β. Mol Cell Biol, 2003, 23(12): 4319-30 [9] Rivers C, Levy A, Hancock J, et al. Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab, 1999, 84(11): 4283-6 [10] McMaster A, Ray DW. Drug insight: selective agonists and antagonists of the glucocorticoid receptor. Nat Clin Pract Endocrinol Metab, 2008, 4(2): 91-101 [11] Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev, 2004, 125(10-11): 697-706 [12] Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol, 2002, 71(1): 9-15 [13] De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factorkappab or activator protein-1: molecular mechanisms for gene repression. Endocr Rev, 2003, 24(4): 488-522 [14] Heck S, Kullmann M, Gast A, et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J, 1994, 13(17): 4087-95 [15] Scott DK, Stromstedt PE, Wang JC, et al. Further characterization of the glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. The role of the glucocorticoid receptor-binding sites. Mol Endocrinol, 1998, 12(4): 482-91 [16] Max SR. Glucocorticoid-mediated induction of glutamine synthetase in skeletal muscle. Med Sci Sports Exerc, 1990, 22(3): 325-30 [17] Hayashi R, Wada H, Ito K, et al. Effects of glucocorticoids on gene transcription. Eur J Pharmacol, 2004, 500(1-3): 51-62 [18] Drouin J, Sun YL, Chamberland M, et al. Novel glucocorticoid receptor complex with DNA element of the hormonerepressed POMC gene. EMBO J, 1993, 12(1): 145-56 [19] Meyer T, Gustafsson JA, Carlstedt-Duke J. Glucocorti-
806 coid-dependent transcriptional repression of the osteocalcin gene by competitive binding at the TATA box. DNA Cell Biol, 1997, 16(8): 919-27 [20] Li CY, Li Y, Li YH, et al. Glucocorticoid repression of human with-no-lysine (K) kinase-4 gene expression is mediated by the negative response elements in the promoter. J Mol Endocrinol, 2008, 40(1): 3-12 [21] Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell, 2002, 109 (Suppl): S81-96 [22] McKay LI, Cidlowski JA. Molecular control of immune/ inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev, 1999, 20(4): 435-59 [23] Gerritsen ME, Williams AJ, Neish AS, et al. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA, 1997, 94(7): 2927-32 [24] Sheppard KA, Phelps KM, Williams AJ, et al. Nuclear integration of glucocorticoid receptor and nuclear factorkappab signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem, 1998, 273(45): 29291-4 [25] Li JW, Lin QS, Yoon HG, et al. Involvement of histone methylation and phosphorylation in regulation of transcription by thyroid hormone receptor. Mol Cell Biol, 2002, 22 (16): 5688-97 [26] Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of I kappa B synthesis. Science, 1995, 270(5234): 286-90 [27] Beck IM, Vanden Berghe W, Vermeulen L. et al. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-κB inhibition. EMBO J, 2008, 27(12): 1682-93 [28] Chen YX, Li ZB, Diao F, et al. Up-regulation of RhoB by glucocorticoids and its effects on the cell proliferation and NF-κB transcriptional activity. J Steroid Biochem Mol Biol, 2006, 101 (4-5):179-87 [29] Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002, 298(5600): 1911-2 [30] Bruna A, Nicolas M, Munoz A, et al. Glucocorticoid receptor-jnk interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J, 2003, 22(22): 6035-44 [31] Kassel O, Schneider S, Heilbock C, et al. A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-κB-regulated promoters. Genes Dev, 2004, 18(20): 2518-28 [32] Lasa M, Abraham, SM, Boucheron C, et al. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol, 2002, 22(22): 7802-11 [33] Hermoso MA, Matsuguchi T, Smoak K, et al. Glucocorticoids and tumor necrosis factor α cooperatively regulate tolllike receptor 2 gene expression. Mol Cell Biol, 2004, 24(11): 4743-56 [34] Kassel O, Sancono A, Kratzschmar J, et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J, 2001, 20(24): 7108-16 [35] Chen RB, Burke TF, Cumberland JE, et al. Glucocorticoids inhibit calcium- and calcineurin-dependent activation of the human IL-4 promoter. J Immunol, 2000, 164(2): 825-32 [36] Reily MM, Pantoja C, Hu X, et al. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J, 2006, 25 (1):108-17 [37] Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol, 1997, 11(9): 1245-55 [38] Belvisi MG, Wicks SL, Battram CH, et al.therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol, 2001, 166(3): 1975-82 [39] Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol, 2003,17(5): 860-9 [40] Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA, 2004, 101 (1): 227-32 [41] Ali A, Thompson CF, Balkovec JM, et al. Novel N- arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity. J Med Chem, 2004, 47(10): 2441-52 [42] De Bosscher K, Vanden Berghe W, Beck IM, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA, 2005, 102(44): 15827-32 [43] Dewint P, Gossye V, De Bosscher K, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J Immunol, 2008, 180(4): 2608-15 [44] Barker M, Clackers M, Copley R, et al. Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series. J Med Chem, 2006, 49(14): 4216-31 [45] Kuzmich D, Kirrane T, Proudfoot J, et al. Identification of dissociated non-steroidal glucocorticoid receptor agonists. Bioorg Med Chem Lett, 2007, 17(18): 5025-31 [46] Miner JN, Ardecky B, Benbatoul K, et al. Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA, 2007, 104(49): 19244-9